Scheen has received lecturer/scientific advisor/clinical investigator fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and NovoNordisk, and has worked as a clinical investigator in the EMPA-REG OUTCOME, CANVAS-R, DECLARE-TIMI 58, LEADER and HARMONY Outcomes cardiovascular outcome trials
In a pooled analysis of phase 2 and 3a clinical trials of liraglutide for weight management, when administered once daily at a dose of 3.0 mg caused no major concerns regarding its neuropsychiatric safety [123]
If you take Ozempic, Wegovy, Mounjaro, Zepbound, semaglutide, tirzepatide, or another GLP-1 medication, you may wonder whether you need to stop it before cosmetic surgery
This approach gives employers more control over their GLP-1 spending than the insurance rider
Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement